Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Outterson

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Annals of Internal Medicine|December 29, 2016
The Fight Against Multidrug-Resistant BacteriaDalia Deak, John H Powers, Kevin Outterson, et al.
Annals of Internal Medicine|May 31, 2016
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015Dalia Deak, Kevin Outterson, John H Powers, et al.
Health Affairs (Project Hope)|February 4, 2015
Repairing the broken market for antibiotic innovationKevin Outterson, John H Powers, Gregory W Daniel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Questions about the 10 x '20 InitiativeKevin Outterson, John H Powers, Ian M Gould, et al.
American Journal of Infection Control|April 23, 2021
The impact of infections on reimbursement in 92 US hospitals, 2015-2018Laura Puzniak, Vikas Gupta, Kalvin C Yu, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-AllTaimur Bhatti, Ka Lum, Silas Holland, et al.
Eclinicalmedicine|September 24, 2025
Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27Maple Goh, Matt McEnany, Rachel Freeman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2021
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020Kevin Outterson, Ebiowei S F Orubu, John Rex, et al.
Plos Medicine|September 30, 2025
Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administrationMaple Goh, A M Viens, Safura Abdool Karim, et al.
Nature Communications|August 2, 2019
Designing development programs for non-traditional antibacterial agentsJohn H Rex, Holly Fernandez Lynch, I Glenn Cohen, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Annals of Internal Medicine|December 29, 2016
The Fight Against Multidrug-Resistant BacteriaDalia Deak, John H Powers, Kevin Outterson, et al.
Annals of Internal Medicine|May 31, 2016
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015Dalia Deak, Kevin Outterson, John H Powers, et al.
Health Affairs (Project Hope)|February 4, 2015
Repairing the broken market for antibiotic innovationKevin Outterson, John H Powers, Gregory W Daniel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Questions about the 10 x '20 InitiativeKevin Outterson, John H Powers, Ian M Gould, et al.
American Journal of Infection Control|April 23, 2021
The impact of infections on reimbursement in 92 US hospitals, 2015-2018Laura Puzniak, Vikas Gupta, Kalvin C Yu, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-AllTaimur Bhatti, Ka Lum, Silas Holland, et al.
Eclinicalmedicine|September 24, 2025
Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27Maple Goh, Matt McEnany, Rachel Freeman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2021
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020Kevin Outterson, Ebiowei S F Orubu, John Rex, et al.
Plos Medicine|September 30, 2025
Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administrationMaple Goh, A M Viens, Safura Abdool Karim, et al.
Nature Communications|August 2, 2019
Designing development programs for non-traditional antibacterial agentsJohn H Rex, Holly Fernandez Lynch, I Glenn Cohen, et al.
Pageof 8